Abstract
Dose escalation in Malignant Mesothelioma (MM): Preliminary report of a phase 2 trial of doxorubicin (D), Ifosfamide (I)/Mesna and rhGM-CSF: J. Van Meerbeeck, L.Y. Dirix, B. Corthouts, A. Prové, P.A. Vermeire, E. Van Marck, A.T. Van Oosterom, University Hospital Antwerp, B-2650 Edegem, Belgium
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
